• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Clover Health Investments Corp. filed SEC Form 8-K: Other Events

    7/17/26 4:05:10 PM ET
    $CLOV
    Medical Specialities
    Health Care
    Get the next $CLOV alert in real time by email
    clov-20260704
    FALSE0001801170CLOVER HEALTH INVESTMENTS, CORP. /DE00018011702026-07-042026-07-04

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 4, 2026

    CLOVER HEALTH INVESTMENTS, CORP.

    (Exact name of Registrant as Specified in Its Charter)

    Delaware
    001-3925298-1515192
    (State or Other Jurisdiction
    (Commission File Number)
    (IRS Employer
    of Incorporation)
    Identification No.)
    Address Not Applicable(1)
    Address Not Applicable(1)
    (Address of Principal Executive Offices)(Zip Code)
    Not Applicable(1)
    (Registrant’s Telephone Number, Including Area Code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


    Securities registered pursuant to Section 12(b) of the Act:

    Trading
    Title of each class
    Symbol(s)
    Name of each exchange on which registered
    Class A Common Stock, par value $0.0001 per shareCLOVThe NASDAQ Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
    (1) We are a remote-first company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices may be directed to the email address: secretary@cloverhealth.com, or to our agent for service of process at The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801.





    Item 8.01. Other Events.
    On July 4, 2026, Clover Health Investments, Corp. (the “Company”) became aware of anomalous login activity on certain of its information systems. The Company immediately activated its incident response procedures, initiated an investigation with assistance from leading third-party cybersecurity experts, and took steps to contain the activity. The Company also notified law enforcement. The investigation subsequently showed that a threat actor gained access to three non-managerial health plan employee accounts through social engineering.
    Based on preliminary findings from the Company’s investigation, those accounts were assigned to employees who had member visit-scheduling and broker-facing sales functions. The employee accounts had access to certain personally identifiable information and protected health information, but had no access to corporate financial or claims systems. While the investigation is ongoing into the precise nature, scope, and extent of data that was subject to unauthorized access and acquisition, the Company believes that its rapid response successfully contained and terminated the unauthorized access.

    Based on information available as of the date of this filing, the Company does not believe that the incident has had, or is reasonably likely to have, a material impact on its business, financial condition or results of operations.

    The Company takes the privacy and security of its member data very seriously and has taken, and continues to take, steps to further harden its IT environment. The Company continues to evaluate applicable regulatory and legal notification requirements and will make all required notifications based on its findings, including to impacted members.

    Forward-Looking Statements

    This Current Report on Form 8-K (the “Form 8-K”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding future events and the Company’s future results of operations, financial condition, market size and opportunity, business strategy and plans, and the factors affecting our performance and our objectives for future operations. Forward-looking statements are not guarantees of future performance and you are cautioned not to place undue reliance on such statements. In some cases, you can identify forward looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "can," "could," "should," "would," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "outlook," "forecast," "guidance," "objective," "plan," "seek," "grow," "if," "continue" or the negative of these words or other similar terms or expressions that concern the Company’s expectations, strategy, priorities, plans or intentions. Forward-looking statements in the Form 8-K include, but are not limited to, the following: estimates regarding the potential impact of the cybersecurity incident, ongoing remediation efforts, future operational recovery and potential financial losses. These forward-looking statements are based on current expectations and are subject to inherent risks, uncertainties, and assumptions that are difficult to predict. Factors that could cause actual results to differ materially include, but are not limited to, the scope and duration of the incident, the nature of the compromised data, the outcome of any regulatory investigations or litigation, and our ability to successfully implement our remediation plans. Additional information concerning these and other risk factors is contained under Item 1A. “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 27, 2026, as such risks may be updated in our subsequent filings with the SEC. The forward-looking statements included in the Form 8-K are made as of the date hereof. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements in the Form 8-K, whether as a result of new information, future events, or otherwise.






    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


    Clover Health Investments, Corp.
    Date:July 17, 2026By:/s/ Karen M. Soares
    Name:Karen M. Soares
    Title:General Counsel and Corporate Secretary


    Get the next $CLOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLOV

    DatePrice TargetRatingAnalyst
    12/17/2024$6.00Buy
    Craig Hallum
    10/7/2024$4.00Neutral
    UBS
    2/25/2022$3.00 → $2.50Market Perform
    SVB Leerink
    2/2/2022$7.00 → $3.00Underperform → Market Perform
    Cowen & Co.
    2/2/2022$6.00Buy
    Canaccord Genuity
    1/19/2022$3.00Market Perform
    SVB Leerink
    1/10/2022$9.00 → $3.50Neutral
    Citigroup
    1/7/2022$9.00 → $3.50Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Loengard Anna U bought $68,755 worth of shares (26,500 units at $2.59) (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/14/25 4:44:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $998,997 worth of shares (446,980 units at $2.23), increasing direct ownership by 32% to 1,856,247 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/8/25 4:07:07 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $999,596 worth of shares (531,700 units at $1.88), increasing direct ownership by 61% to 1,409,267 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/13/24 4:06:53 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clover Health to Report Second Quarter 2026 Financial Results on August 5, 2026

    WILMINGTON, Del., July 09, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, August 5, 2026. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial performance for the quarter. Second Quarter 2026 Conference Webcast Details: What: Clover Health’s Second Quarter 2026 Earnings Conference CallWhen: Wednesday, August 5, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-2q-2026-earning

    7/9/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up

    SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or "Clover Health"), and a leading AI-powered physician enablement platform, today released findings within the whitepaper "Clinical Excellence in Continuity of Care: A Real-World Analysis of Counterpart Assistant's Role in Post-Hospitalization Follow-up." The whitepaper examines the relationship between CA use by primary care physicians ("PCPs") and performance on high-risk care transition outcomes, including two HEDIS®1 quality measures within Clover Health’s Medicare Advantage population: Transitions of Care ("

    7/7/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Reports First Quarter 2026 Results

    Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross ProfitMarket-leading Medicare Advantage membership growth with underlying trends tracking in line with expectationsExpect to meet or exceed full year 2026 outlook across all metrics, including achieving first full year GAAP Net Income profitability Financial Results: First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-yearFirst quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-yearFirst q

    5/6/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Soares Karen sold $233,167 worth of shares (51,700 units at $4.51) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,505,522 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    7/20/26 5:48:55 PM ET
    $CLOV
    Medical Specialities
    Health Care

    CEO, Medicare Advantage Reynoso Jamie L. sold $21,921 worth of shares (4,839 units at $4.53) as part of a pre-agreed trading plan, decreasing direct ownership by 0.17% to 2,814,640 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    7/17/26 5:26:40 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Chief Executive Officer Toy Andrew sold $292,860 worth of shares (62,711 units at $4.67), decreasing direct ownership by 0.65% to 9,547,114 units (SEC Form 4) (tax withholding)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    7/16/26 4:59:19 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    SEC Filings

    View All

    Clover Health Investments Corp. filed SEC Form 8-K: Other Events

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    7/17/26 4:05:10 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Investments Corp. filed SEC Form 8-K: Other Events

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    6/18/26 4:05:28 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Investments Corp. filed SEC Form 8-K: Leadership Update

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    6/16/26 4:05:44 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Clover Health with a new price target

    Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00

    12/17/24 8:33:41 AM ET
    $CLOV
    Medical Specialities
    Health Care

    UBS initiated coverage on Clover Health with a new price target

    UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00

    10/7/24 7:45:42 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SVB Leerink reiterated coverage on Clover Health Investments with a new price target

    SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

    2/25/22 5:03:33 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Leadership Updates

    Live Leadership Updates

    View All

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Celebrates the Election of Dr. Ian Duncan, Clover MA Board Member, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries

    WILMINGTON, Del., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today celebrates the appointment of Dr. Ian Duncan, Ph.D., FSA, FIA, FCIA, FCA, CSPA MAAA, a member of Clover's Medicare Advantage Board of Directors, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA). On September 12, 2025, the SOA announced that Dr. Duncan will become the 78th President and Chair at the 2026 SOA ImpACT Annual Conference. With roots dating back to 1889, the SOA is the world's largest actuarial

    9/18/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution

    WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today announced the appointment of Vicky Bruner as Vice President of Operations. As Counterpart scales to meet growing demand from payors and providers nationwide, Bruner will lead several critical functions including customer implementations, provider network engagement, clinician onboarding and training, and longitudinal account support. Her work will be foundational, ensuring operational readiness and delivery consisten

    7/29/25 4:30:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Financials

    Live finance-specific insights

    View All

    Clover Health to Report Second Quarter 2026 Financial Results on August 5, 2026

    WILMINGTON, Del., July 09, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, August 5, 2026. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial performance for the quarter. Second Quarter 2026 Conference Webcast Details: What: Clover Health’s Second Quarter 2026 Earnings Conference CallWhen: Wednesday, August 5, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-2q-2026-earning

    7/9/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Reports First Quarter 2026 Results

    Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross ProfitMarket-leading Medicare Advantage membership growth with underlying trends tracking in line with expectationsExpect to meet or exceed full year 2026 outlook across all metrics, including achieving first full year GAAP Net Income profitability Financial Results: First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-yearFirst quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-yearFirst q

    5/6/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026

    WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. First Quarter 2026 Conference Webcast Details: What: Clover Health's First Quarter 2026 Earnings Conference CallWhen: Wednesday, May 6, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-1q26-earnings-call.ope

    4/8/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    11/12/24 2:31:31 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    11/4/24 11:25:56 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Clover Health Investments Corp. (Amendment)

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    7/7/23 4:35:52 PM ET
    $CLOV
    Medical Specialities
    Health Care